Given the pervasiveness of alcohol use disorders (AUDs) in the United States, Dr. Mark Willenbring says, “we need to be intervening at a much earlier stage and providing treatment to a much broader range of people then we currently do.” Dr. Willenbring, director of the National Institute on Alcohol Abuse and Alcoholism's Division of Treatment and Recovery Research, joins host Dr. Larry Kaskel to talk about new information from epidemiologic research on the prevalence and progression of heavy drinking and alcohol use disorders. In addition, Dr. Willenbring discusses the subtypes of alcohol dependence, and the nature of AUDs, in the context of DSM revisions.
Alcohol Use Disorders: Can We Do More?
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Given the pervasiveness of alcohol use disorders (AUDs) in the United States, Dr. Mark Willenbring says, “we need to be intervening at a much earlier stage and providing treatment to a much broader range of people then we currently do.” Dr. Willenbring, director of the National Institute on Alcohol Abuse and Alcoholism's Division of Treatment and Recovery Research, joins host Dr. Larry Kaskel to talk about new information from epidemiologic research on the prevalence and progression of heavy drinking and alcohol use disorders. In addition, Dr. Willenbring discusses the subtypes of alcohol dependence, and the nature of AUDs, in the context of DSM revisions.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
0.25 credits
<p>Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
CME/CE Broadcast Replay
Love Story: Lipid Education for Women’s Heart Health
0.50 credits
<p>Love Story: Lipid Education for Women’s Heart Health</p>
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
<p>Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?